news_6

InnoCare Announces the Approval of Orelabrutinib in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma

BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced today that its BTK inhibitor orelabrutinib received approval from the...

resize-qq-24

The 24th National Invention Exhibition-One Belt One Road & BRICS Skills Development and Technology Innovation Competition concluded in Foshan, China

Hong Kong scientists applied 5G beamforming technology to develop revolutionary hearing aids, effectively reducing noise by 90%. Won the "Most...

news_6

Aurora Tele-Oncology’s strategic partnership with UMP Healthcare to launch quality cross-border oncology telemedicine services in Mainland China

HONG KONG SAR - Media OutReach - 28 December 2020 - Aurora Tele-Oncology Limited ("Aurora Tele-Oncology") recently announced a strategic partnership with Hainan...